Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469518 | 0.83 | MTNR1A (0.50) | MTNR1AMTNR1BSLC6A4LMNALTA4H | |
| SCHEMBL1454240 | 0.81 | MTNR1A (0.49) | MTNR1AMTNR1BSLC6A4LMNALTA4H | |
| SCHEMBL11613012 | 0.80 | ALDH1A1 (0.41) | MTNR1AMTNR1BSLC6A4LMNAPOLB | |
| SCHEMBL28546046 | 0.80 | SLC6A4 (0.39) | MTNR1AMTNR1BSLC6A4LMNAPOLB | |
| SCHEMBL11614077 | 0.80 | SIGMAR1 (0.50) | SLC6A4POLBCYP1A2GAACYP2C9 | |
| SCHEMBL8515621 | 0.80 | ESR2 (0.38) | MTNR1AMTNR1BLTA4HPTGS1 | |
| SCHEMBL218384 | 0.79 | MTNR1A (0.47) | MTNR1AMTNR1BSLC6A4LMNALTA4H | |
| SCHEMBL27629520 | 0.79 | MTNR1A (0.51) | MTNR1AMTNR1BSLC6A4LMNALTA4H | |
| SCHEMBL7582723 | 0.79 | MTNR1A (0.47) | MTNR1AMTNR1BSLC6A4LMNALTA4H | |
| SCHEMBL7404204 | 0.79 | MTNR1A (0.47) | MTNR1AMTNR1BSLC6A4LMNALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1076649-A1 | ISOQUINOLINE COMPOUND MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME | TREGA BIOSCIENCES, INC. (US) | 2001-02-21 | — | — | EP | claimed |
| US-6127381-A | A MELANOCORTIN RECEPTOR LIGAND FOR REGULATING FOOD INTAKE AND BODY WEIGHT, REGULATING CYTOKINE ACTIVITY, ANTI-INFLAMMATORY ACTIVITY | LION BIOSCIENCE AG (DE) | 2000-10-03 | — | — | US | claimed |
| WO-1999055679-A1 | ISOQUINOLINE COMPOUND MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME | TREGA BIOSCIENCES, INC. (US) | 1999-11-04 | — | — | WO | claimed |
| CN-107918247-B | Colored curable resin composition | 住友化学株式会社 | 2022-03-18 | — | — | CN | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| CN-106019840-B | Colored curable resin composition | 东友精细化工有限公司 | 2021-01-29 | — | — | CN | disclosed |
| CN-112154167-A | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2020-12-29 | — | — | CN | disclosed |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| CN-111315828-A | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2020-06-19 | — | — | CN | disclosed |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-31 | — | — | US | disclosed |
| WO-2020021969-A1 | COMPOSITION, CURED PRODUCT, OPTICAL FILTER, AND PRODUCTION METHOD FOR CURED PRODUCT | 株式会社ADEKA | 2020-01-30 | — | — | WO | disclosed |
| US-6127381-A | A MELANOCORTIN RECEPTOR LIGAND FOR REGULATING FOOD INTAKE AND BODY WEIGHT, REGULATING CYTOKINE ACTIVITY, ANTI-INFLAMMATORY ACTIVITY | LION BIOSCIENCE AG (DE) | 2000-10-03 | — | — | US | disclosed |
| WO-1999055679-A1 | ISOQUINOLINE COMPOUND MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME | TREGA BIOSCIENCES, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
| US-4122282-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-10-24 | — | — | US | disclosed |
| US-4099014-A | BLOOD PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
| US-4085139-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-04-18 | — | — | US | disclosed |
| US-4081478-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
| US-4073808-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-02-14 | — | — | US | disclosed |
| US-4033989-A | 9-Deoxy-PGF2 Analogs | THE UPJOHN COMPANY (US) | 1977-07-05 | — | — | US | disclosed |
| US-4016184-A | PROSTAGLANDINS, BLOOD PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | MTNR1A 49/4885MTNR1B 110/4885SLC6A4 115/4885 |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | MTNR1A 76/4885MTNR1B 91/4885SLC6A4 95/4885 |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | MC2R, PNMT, SLC6A2 | MTNR1A 29/4885MTNR1B 41/4885SLC6A4 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.